Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Liver fibrosis regression after hepatitis C treatment linked to reduced complications and death in people with HIV and HCV co-infection

People with HIV and HCV co-infection, with liver cirrhosis, who achieve sustained virological response (SVR) and experience an improvement in liver fibrosis are less likely to develop liver

Published
4 hours ago
By
Liz Highleyman
China progresses in hepatitis B vaccination, more treatment effort urged

China has won praises from WHO after reaching its goal to control hepatitis B infection among children through immunization ahead of schedule, but more effort is urged for its adult patients.

Published
27 July 2015
From
Xinhua
Georgia sets sights on eliminating hepatitis C

A combination of strong political will, public support and experience gained in HIV prevention and control led to this new programme. The Ministry of Labour, Health and Social Affairs is working with a pharmaceutical manufacturer to provide an initial 5000 courses of DAAs as the first part of the programme, followed by 20 000 treatment courses annually free of charge.

Published
27 July 2015
From
WHO Europe
Viral hepatitis – 400 deaths a day in the WHO European Region could be prevented

Over 13 million people in the WHO European Region are living with chronic hepatitis B infection and over 15 million with chronic hepatitis C infection. Two-thirds of those infected are in eastern Europe and Central Asia. Hepatitis B and C infections lead to 400 deaths in the Region every day.

Published
27 July 2015
From
WHO Europe
FDA OK’s BMS Daklinza (Daclatasvir) to Treat Hep C Genotype 3

The FDA has approved BMS's Daklinza (daclatasvir) to be used with Gilead Sciences’ Sovaldi (sofosbuvir) to treat genotype 3 of hepatitis C.

Published
27 July 2015
From
AIDSMeds
FDA approves Technivie for treatment of chronic hepatitis C genotype 4

The U.S. Food and Drug Administration today approved Technivie (ombitasvir, paritaprevir and ritonavir) for use in combination with ribavirin for the treatment of hepatitis C virus (HCV) genotype 4 infections in patients without scarring and poor liver function (cirrhosis).

Published
27 July 2015
From
FDA
How Sure Is a Cure?

Once you’ve officially rid yourself of hepatitis C, how certain can you be that the virus is gone for good?

Published
20 July 2015
From
Poz
Gilead Limits Enrollment in its Hep C Patient Program to Pressure Insurers

In a bid to push back against payers, Gilead Sciences is limiting enrollment to its patient assistance program for hepatitis C drugs, which helps people obtain the Sovaldi and Harvoni treatments when they lack sufficient insurance coverage or the financial wherewithal to get the medicines otherwise.

Published
20 July 2015
From
Wall Street Journal Pharmalot blog
Access to screening and treatment are key issues for hepatitis B and C and HIV/viral hepatitis co-infection

The development of effective new interferon-free treatment makes it possible to cure more than 90% of people with chronic hepatitis C, including most people with HIV and hepatitis

Published
20 July 2015
By
Liz Highleyman
Gilead Limits Enrollment in its Hep C Patient Program to Pressure Insurers

The drug maker is taking this step after finding that some payers, despite receiving discounts in recent months, have continued to restrict patient access to its hepatitis C medicines. As a result, Gilead has been picking up the cost of the medicines for more people it would like seeking patient assistance, according to a July 1 letter sent to patient groups and community health providers, among others.

Published
19 July 2015
From
Wall Street Journal
← First12345...172Next →

Filter by country